HIND

$2.12

Pre-MarketAs of Mar 17, 8:00 PM UTC

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.12
Potential Upside
5%
Whystock Fair Value$2.23
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.86

Recent News

Simply Wall St.
Dec 29, 2025

We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investing.com
Aug 15, 2025

Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market

Investing.com -- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.